Xolair (Genentech Inc) en es it fr

Xolair (Genentech Inc) Brand names, Xolair (Genentech Inc) Analogs

Xolair (Genentech Inc) Brand Names Mixture

  • No information avaliable

Xolair (Genentech Inc) Chemical_Formula


Xolair (Genentech Inc) RX_link


Xolair (Genentech Inc) fda sheet

Xolair (Genentech Inc) msds (material safety sheet)

Xolair (Genentech Inc) Synthesis Reference

Sequence in Presta et al., J. of Immunol. 151, 2623 1993

Xolair (Genentech Inc) Molecular Weight


Xolair (Genentech Inc) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Xolair (Genentech Inc) H2O Solubility

No information avaliable

Xolair (Genentech Inc) State


Xolair (Genentech Inc) LogP


Xolair (Genentech Inc) Dosage Forms

Powder for solution

Xolair (Genentech Inc) Indication

For treatment of asthma caused by allergies

Xolair (Genentech Inc) Pharmacology

Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.

Xolair (Genentech Inc) Absorption

No information avaliable

Xolair (Genentech Inc) side effects and Toxicity

No information avaliable

Xolair (Genentech Inc) Patient Information

No information avaliable

Xolair (Genentech Inc) Organisms Affected

Humans and other mammals